Form 4: Mineralys Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
James J. Ferguson Iii, Chief Medical Officer of Mineralys Therapeutics, Inc., reported multiple transactions in common stock on August 10, 2026.
Summary
- Grant/award: acquired 102,400 Common Stock on August 10, 2026; holds 102,400 after (Direct).
- Grant/award: acquired 135,000 Stock Option on August 10, 2026; holds 135,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James J. Ferguson Iii — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Grant/award | Common Stock | 102,400 | — | — | 102,400 |
| 2026-08-10 | Grant/award | Stock Option | 135,000 | — | — | 135,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Grant/award (102,400 shares) |
| 2026-08-10 | Grant/award (135,000 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., neutral, James J. Ferguson Iii
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.